Oorja Bio, Inc.
PrivateLast Round
Series A
May 19, 2026
Total Funding Raised
$30M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Oorja Bio is a clinical-stage biotechnology company developing therapies for idiopathic pulmonary fibrosis (IPF) and other fibrotic and cardiopulmonary diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Oorja Bio, Inc. Comparables
Compare Oorja Bio, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Rein Therapeutics | 85% | |
| Celea Therapeutics | 83% | |
| Pulmongene | 79% | |
Oorja Bio, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | May 19, 2026 |
Oorja Bio, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Westlake Village BioPartners | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 19, 2026
$30M round led by Westlake Village Biopartners
Oorja Bio, Inc. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Oorja Bio, Inc.'s valuation, stock price, and market status.